Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
25.61
-0.39 (-1.50%)
At close: Mar 2, 2026, 4:00 PM EST
25.23
-0.38 (-1.48%)
Pre-market: Mar 3, 2026, 5:49 AM EST
Evommune Revenue
Evommune had revenue of $10.00M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $13.00M. In the year 2024, Evommune had annual revenue of $7.00M with 40.00% growth.
Revenue (ttm)
$13.00M
Revenue Growth
+40.00%
P/S Ratio
62.10
Revenue / Employee
$288,889
Employees
45
Market Cap
807.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEVMN News
- 18 days ago - Evommune Announces $125 Million Private Placement - Business Wire
- 18 days ago - Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Benzinga
- 20 days ago - Evommune's Stock Surges On Strong Results For New Eczema Drug - Benzinga
- 20 days ago - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Business Wire
- 2 months ago - Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Evommune Announces Pricing of its Initial Public Offering - PRNewsWire
- 4 months ago - Evommune Announces Commencement of Initial Public Offering - PRNewsWire
- 4 months ago - Evommune Aims For IPO In Bifurcated Biopharma Market - Seeking Alpha